New anticoagulants: A concise review

被引：23

作者：

Kreuziger, Lisa M. Baumann ^{[1
]}

Morton, Colleen T. ^{[1
]}

Dries, David J. ^{[2
]}

机构：

[1] Univ Minnesota, Dept Hematol Oncol & Transplant, Minneapolis, MN 55455 USA

[2] Univ Minnesota, Reg Hosp, Dept Surg, Minneapolis, MN 55455 USA

来源：

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY | 2012年 / 73卷 / 04期

关键词：

Anticoagulation; thromboembolism; dabigatran; rivaroxaban; apixaban; DIRECT THROMBIN INHIBITOR; FACTOR XA INHIBITOR; ACUTE CORONARY SYNDROMES; TOTAL HIP-REPLACEMENT; DEEP-VEIN THROMBOSIS; DABIGATRAN ETEXILATE; DOUBLE-BLIND; VENOUS THROMBOEMBOLISM; ANTIPLATELET THERAPY; KNEE REPLACEMENT;

D O I：

10.1097/TA.0b013e318265cf9e

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

During the last 2 years, two new oral anticoagulants, dabigatran and rivaroxaban, have been approved in the United States. Phase II and Phase III clinical trials of dabigatran, rivaroxaban, and apixaban are summarized. Approach to perioperative management depends on the half-life of the medication, risk of surgical bleeding, and the patient's renal function. No reversal agent is available for any of the new oral anticoagulants. Management of bleeding patients is based on local measures and consideration of antifibrinolytic therapy and activated factor VII or prothrombin complex concentrate infusion based on healthy volunteer and animal studies. The new oral anticoagulants provide additional options to prevent venous thromboembolism in patients after orthopedic surgery or stroke in patients with atrial fibrillation but present unique challenges compared to warfarin. (J Trauma Acute Care Surg. 2012; 73: 983-992. Copyright (C) 2012 by Lippincott Williams & Wilkins)

引用

页码：983 / 992

页数：10

共 53 条

[1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Ageno, Walter ;

Gallus, Alexander S. ;

Wittkowsky, Ann ;

Crowther, Mark ;

Hylek, Elaine M. ;

Palareti, Gualtiero .

CHEST, 2012, 141 (02) :E44S-E88S

[2] Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study [J].

Agnelli, Giancarlo ;

Gallus, Alexander ;

Goldhaber, Samuel Z. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Hull, Russel D. ;

Kakkar, Ajay K. ;

Misselwitz, Frank ;

Schellong, Sebastian .

CIRCULATION, 2007, 116 (02) :180-187

[3] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome [J].

Alexander, John H. ;

Lopes, Renato D. ;

James, Stefan ;

Kilaru, Rakhi ;

He, Yaohua ;

Mohan, Puneet ;

Bhatt, Deepak L. ;

Goodman, Shaun ;

Verheugt, Freek W. ;

Flather, Marcus ;

Huber, Kurt ;

Liaw, Danny ;

Husted, Steen E. ;

Lopez-Sendon, Jose ;

De Caterina, Raffaele ;

Jansky, Petr ;

Darius, Harald ;

Vinereanu, Dragos ;

Cornel, Jan H. ;

Cools, Frank ;

Atar, Dan ;

Luis Leiva-Pons, Jose ;

Keltai, Matyas ;

Ogawa, Hisao ;

Pais, Prem ;

Parkhomenko, Alexander ;

Ruzyllo, Witold ;

Diaz, Rafael ;

White, Harvey ;

Ruda, Mikhail ;

Geraldes, Margarida ;

Lawrence, Jack ;

Harrington, Robert A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) :699-708

[4] Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial [J].

Alexander, John H. ;

Becker, Richard C. ;

Bhatt, Deepak L. ;

Cools, Frank ;

Crea, Filippo ;

Dellborg, Mikael ;

Fox, Keith A. A. ;

Goodman, Shaun G. ;

Harrington, Robert A. ;

Huber, Kurt ;

Husted, Steen ;

Lewis, Basil S. ;

Lopez-Sendon, Jose ;

Mohan, Puneet ;

Montalescot, Gilles ;

Ruda, Mikhail ;

Ruzyllo, Witold ;

Verheugt, Freek ;

Wallentin, Lars ;

Darius, Harald ;

Simoons, Maarten ;

Boersma, Eric ;

DeLemos, James ;

Spencer, Fred .

CIRCULATION, 2009, 119 (22) :2877-U39

[5]

[Anonymous], 2011, XAR PRESCR INF

[6] Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].

Bauersachs, Rupert ;

Berkowitz, Scott D. ;

Brenner, Benjamin ;

Buller, Harry R. ;

Decousus, Herve ;

Gallus, Alex S. ;

Lensing, Anthonie W. ;

Misselwitz, Frank ;

Prins, Martin H. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Bounameaux, Henri ;

Cohen, Alexander ;

Davidson, Bruce L. ;

Piovella, Franco ;

Schellong, Sebastian .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510

[7] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].

Beasley, B. Nhi ;

Unger, Ellis F. ;

Temple, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790

[8] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor [J].

Becker, Richard C. ;

Yang, Hongqiu ;

Barrett, Yuchen ;

Mohan, Puneet ;

Wang, Jessie ;

Wallentin, Lars ;

Alexander, John H. .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) :183-187

[9] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study [J].

Buller, H. ;

Deitchman, D. ;

Prins, M. ;

Segers, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) :1313-1318

[10]

Clav A, 2012, ORTHOP TRAUMATOL SUR

← 1 2 3 4 5 6 →